- Pharmaceutical industry | Definition, Overview, History . . .
The pharmaceutical industry entails the discovery, development, and manufacture of drugs and medications (pharmaceuticals) by public and private organizations
- Sackler family | Brothers, OxyContin, Purdue Pharma, Opioid Epidemic . . .
The Sackler family formerly owned the pharmaceutical company Purdue Pharma, known for developing the highly addictive drug OxyContin They gave up control of the company in 2025 as part of a settlement for their involvement in the opioid epidemic
- Dilip Shanghvi | Biography Facts | Britannica Money
Aside from his work at Sun Pharma, Shanghvi was active as a personal investor, with interests that increasingly extended beyond pharmaceuticals, notably in the field of renewable energy
- Johnson Johnson | History, Products, Controversies | Britannica Money
Johnson Johnson is the world’s second largest drug and biotechnology company by market capitalization, behind Eli Lilly (LLY) but ahead of other “big pharma” competitors such as AbbVie (ABBV), Novartis (NVS), and Merck (MRK)
- Prescription Drug Costs - Encyclopedia Britannica
Melissa Pistilli, “10 Top Pharma Companies by Revenue” (December 9, 2021), investingnews com Drug Discovery Development, “Pharma 50: The 50 Largest Pharmaceutical Companies in the World” (accessed March 30, 2022), drugdiscoverytrends com
- The Opioid Crisis | Britannica
Sackler family, American family, former owners of the pharmaceutical company Purdue Pharma Although the family is well known
- Pharmaceuticals, Vaccines, Facts - Britannica Money
Like most “big pharma” companies, AstraZeneca’s future depends on its ability to: Maintain a pipeline of new and improved treatments in order to manage its revenue streams as patents for its key drugs expire The company has upped its R D spending in recent years, spending nearly $11 billion in 2023 on its pipeline of over 150 projects
- McKinsey Company | Consulting Firm, Controversies, Facts - Britannica
The company also worked with Purdue Pharma, the maker of OxyContin, throughout the opioid crisis Sales of the drug had been declining, so McKinsey wrote proposals with the goal to “turbocharge” its sales, ultimately making about $86 million for consulting for Purdue
|